Two recent studies found that as many as 20 percent of adults may have disease-associated variants, despite having no symptoms or evidence of family history.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
The Stanford University and Fox Chase Cancer Center team found that some mutations dramatically increased cancer risk, while others had a more modest effect.
Even in schizophrenia cases lacking intellectual disability, investigators found that rare mutations in genes normally resistant to loss-of-function changes were enriched.
The company launched the MassArray System with Chip Prep Module in Europe for general IVD use, targeting hospitals and laboratories.
The Triple Quad 4500MD LC-MS/MS system, which consists of the LC-MS/MS platform along with Sciex's Analyst MD, Cliquid MD, and MultiQuant MD software, can be used for in vitro diagnostics.
The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
DuPont Pioneer has acquired the exclusive rights to ERS Genomics' portfolio of CRISPR-Cas genome-editing technologies for all plant and agricultural applications.
Patients who've learned their genetic risk of disease worry about healthcare law changes in the US, Kaiser Health News reports.
Hopkins' Geoffrey Ling discusses the promise of genomic vaccines at Scientific American.
In Nature this week: mitochondrial genome of extinct South American ungulate, and more.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.